The broader comparison across GLP-1 compounds consistently places retatrutide at the top of efficacy rankings, though with correspondingly higher side effect rates
In tirzepatide users, the researchers reported that a missense variant in GIPR, rs1800437, increased the risk of vomiting, and estimated that people homozygous for risk alleles at both GLP1R and GIPR had a 14.8fold higher odds of tirzepatiderelated vomiting than those without risk alleles
Cole MA, Abd Jamil AH, Heather LC, Murray AJ, Sutton ER, Slingo M, Sebag-Montefiore L, Tan SC, Aksentijevi D, Gildea OS, Stuckey DJ, Yeoh KK, Carr CA, Evans RD, Aasum E, Schofield CJ, Ratcliffe PJ, Neubauer S, Robbins PA, Clarke K (2016) On the pivotal role of PPAR in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury
Additionally, new users in the later period were slightly more likely to have a historical (22.9% vs
Glucagon-like peptide-1 receptor agonists (semaglutide and tirzepatide) are a class of medications approved by the U.S
